drugset / Trial / NCT05800873
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Non-randomizedSingle-groupOpen-labelTreatment
Summary
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2026-09-15
- Completion
- 2026-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVER001 | Unknown | 100 mg | Oral |
| Subject | EVER001 | Unknown | 200 mg | Oral |